Literature DB >> 8006584

Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.

T Nakarai1, M J Robertson, M Streuli, Z Wu, T L Ciardelli, K A Smith, J Ritz.   

Abstract

The interleukin 2 receptor (IL-2R) is known to be comprised of at least three genetically distinct subunits termed alpha, beta, and gamma. These chains can be expressed individually or in various combinations resulting in distinct receptors with different affinities for IL-2. In contrast to alpha and beta, the cell surface expression of the gamma chain protein previously has not been well-characterized. To examine cell surface expression of IL-2R gamma on hematopoietic cells, we developed two new monoclonal antibodies (mAbs) specific for this protein. Both 1A11 (immunoglobulin [IgG1]) and 3G11 (IgM) specifically reacted with murine cells transfected with IL-2R gamma cDNA, and immunoprecipitation studies indicated that both antibodies precipitated a protein of approximately 62-65 kD. Scatchard analysis of IL-2 binding to murine cells transfected with cDNA-encoding combinations of IL-2R components demonstrated that neither beta nor gamma chain bind IL-2 with measurable affinity, but coexpression of both beta and gamma is sufficient to form an intermediate affinity receptor. In the absence of gamma chain, beta chain interacts with alpha chain to form a "pseudo-high" affinity receptor. In contrast, gamma chain does not appear capable of interacting with alpha in the absence of beta chain. Thus, gamma chain appears to interact only with beta, but beta chain is capable of interacting with both alpha and gamma. Using the newly developed mAbs to examine cell surface expression by immunofluorescence, resting T cells were found to express low levels of gamma chain without detectable alpha or beta. Early after mitogen stimulation, T cells expressed higher levels of alpha, beta, and gamma. However, at later time points, T cells expressed alpha and gamma in marked excess over beta. Thus, formation of high affinity IL-2R on activated T cells was primarily limited by beta chain expression. In contrast, resting natural killer (NK) cells constitutively expressed IL-2R beta without detectable alpha or gamma. After activation with either IL-2 or IL-12, expression of both alpha and gamma transiently increased and then returned to very low levels. Expression of functional IL-2R on resting and activated NK cells, therefore, appeared to be primarily limited by the expression of gamma chain. IL-2 binding studies with resting NK cells confirmed the results of immunofluorescence studies indicating the presence of very low numbers of intermediate affinity (beta gamma) receptors for IL-2 on these cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006584      PMCID: PMC2191535          DOI: 10.1084/jem.180.1.241

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

1.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.

Authors:  Y Takebe; M Seiki; J Fujisawa; P Hoy; K Yokota; K Arai; M Yoshida; N Arai
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

2.  Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions.

Authors:  M Sharon; R D Klausner; B R Cullen; R Chizzonite; W J Leonard
Journal:  Science       Date:  1986-11-14       Impact factor: 47.728

3.  The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit.

Authors:  D Güssow; R Rein; I Ginjaar; F Hochstenbach; G Seemann; A Kottman; H L Ploegh
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

4.  Cell surface phenotype of a cloned line of human natural killer cells.

Authors:  J Kornbluth; N Flomenberg; B Dupont
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

5.  A restricted cytoplasmic region of IL-2 receptor beta chain is essential for growth signal transduction but not for ligand binding and internalization.

Authors:  M Hatakeyama; H Mori; T Doi; T Taniguchi
Journal:  Cell       Date:  1989-12-01       Impact factor: 41.582

6.  Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes.

Authors:  M Malkovský; B Loveland; M North; G L Asherson; L Gao; P Ward; W Fiers
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

Review 7.  Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way.

Authors:  S D Voss; R Hong; P M Sondel
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

8.  Characterization of the human receptor for T-cell growth factor.

Authors:  W J Leonard; J M Depper; R J Robb; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

9.  A monoclonal antibody to human acute lymphoblastic leukaemia antigen.

Authors:  J Ritz; J M Pesando; J Notis-McConarty; H Lazarus; S F Schlossman
Journal:  Nature       Date:  1980-02-07       Impact factor: 49.962

10.  Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens.

Authors:  M Streuli; L R Hall; Y Saga; S F Schlossman; H Saito
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  28 in total

1.  A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.

Authors:  M L Boytim; P Lilly; K Drouvalakis; S C Lyu; R Jung; A M Krensky; C Clayberger
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers.

Authors:  K Araki; K Harada; K Nakamoto; M Shiroma; T Miyakuni
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

3.  Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis.

Authors:  D Girard; R Paquin; A D Beaulieu
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

4.  IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain.

Authors:  R L Palmer-Crocker; C C Hughes; J S Pober
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 5.  The common γ-chain cytokine receptor: tricks-and-treats for T cells.

Authors:  Adam T Waickman; Joo-Young Park; Jung-Hyun Park
Journal:  Cell Mol Life Sci       Date:  2015-10-14       Impact factor: 9.261

Review 6.  X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis.

Authors:  N L Farner; S D Voss; P M Sondel
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

7.  Staphylococcal enterotoxins modulate interleukin 2 receptor expression and ligand-induced tyrosine phosphorylation of the Janus protein-tyrosine kinase 3 (Jak3) and signal transducers and activators of transcription (Stat proteins).

Authors:  M Nielsen; A Svejgaard; C Röpke; M Nordahl; N Odum
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Interleukin 2 modulates ion secretion and cell proliferation in cultured human small intestinal enterocytes.

Authors:  E V O'Loughlin; G P Pang; R Noltorp; C Koina; R Batey; R Clancy
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

9.  Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.

Authors:  E L Jacobson; F Pilaro; K A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

10.  Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.

Authors:  J A Gollob; C P Schnipper; E Orsini; E Murphy; J F Daley; S B Lazo; D A Frank; D Neuberg; J Ritz
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.